Updated molecular epidemiology of carbapenem-non-susceptible *Escherichia coli* in Taiwan: first identification of KPC-2 or NDM-1-producing *E. coli* in Taiwan

Ling Ma¹, L Kristopher Siu¹, Jung-Chung Lin², Tsu-Lan Wu³, Chang-Phone Fung⁴, Jann-Tay Wang⁵, Po-Liang Lu⁶,⁷* and Yin-Ching Chuang⁸,⁹*

**Abstract**

**Background:** The global spread and increasing incidence of carbapenem-resistant Enterobacteriaceae have resulted in treatment and public health concerns. Here, we present an investigation of the molecular mechanisms and clonality of carbapenem-non-susceptible *Escherichia coli* (CnSEC) based on a nationwide survey in Taiwan.

**Methods:** We collected 32 and 43 carbapenem-non-susceptible *E. coli* isolates in 2010 and 2012, respectively. The genes encoding carbapenemases and plasmidic AmpC-type and extended-spectrum β-lactamases (EBSLs) were analyzed by polymerase chain reaction (PCR). The major porin channels OmpF and OmpC were evaluated by sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE). Molecular typing was performed with pulsed-field gel electrophoresis (PFGE) and multi-locus sequence typing (MLST).

**Results:** The resistance rates of CnSEC isolates to cefazolin, cefotaxime, cefoxitin, ceftazidime, and ertapenem were all 100%, and most (94.7%) isolates were CMY producers. The main mechanism of CnSEC in Taiwan is via plasmidic AmpC β-lactamase CMY-2 and DHA-1 in combination with the loss of OmpC/F. In 2010, one isolate was confirmed to harbor *bla*IMP-8; a KPC-2 producer and an NDM-1 producer were detected in 2012. No isolate had VIM- or OXA-carbapenemases. ST131 was the predominant ST type (33.3%). PFGE revealed no large cluster in CnSEC isolates in Taiwan.

**Conclusions:** The co-existence of plasmidic AmpC β-lactamase and outer membrane protein loss is the main mechanism for CnSEC in Taiwan. The emergence of KPC-2 and NDM-1 in 2012 and the predominance of ST131 warrant close monitoring and infection control.

**Background**

*Escherichia coli* is an important member of Enterobacteriaceae that is evolving drug resistance mechanisms. Extended-spectrum β-lactamases (ESBLs) conferring resistance to extended-spectrum cephalosporins lead to treatment failure by penicillins and cephalosporins and are prevalent in *E. coli* isolates from hospital patients, community members, farm animals, and food. Carbapenems are powerful antibiotics that are not inactivated by ESBLs and AmpC β-lactamases and therefore are regarded as the last line of treatment for infections by ESBL producers. Carbapenem resistance in Enterobacteriaceae, particularly *Klebsiella pneumoniae*, has recently been reported worldwide, whereas carbapenem-resistant *E. coli* is relatively rare [1]. Nonetheless, carbapenem resistance in *E. coli* should be closely monitored because of its potential to spread in both hospital and community settings [2]. The mechanisms of carbapenem resistance in Enterobacteriaceae are the presence of either carbapenemase or a combination of β-lactamases and porin loss [3-7]. There are three types of carbapenemases that hydrolyze...
carbapenems, including class A (penicillinas), class B (metallo-β-lactamasases), and class D (oxacillinase). Although IMP- and VIM-MBLs have typically been the most common types of MBLs found in Enterobacteriaceae [8], KPC (class A) enzymes are now the most predominant carbapenemases worldwide [9]. Carbapenemase-harboring E. coli is relatively less reported, though the first report of KPC-2 in E. coli was in 2006 [10]. This could be because carbapenem resistance does not occur naturally in E. coli [11], and it has been reported that plasmid transfer between K. pneumoniae and E. coli does not readily occur [12].

With regard to ESBL-producing E. coli, pandemic E. coli MLST type ST131 with CTX-M β-lactamase is spreading [13]; thus, whether the spread of carbapenem resistance in E. coli is related to certain clones warrants investigation. Accordingly, we initiated a nationwide surveillance program in 2010 and 2012 to investigate the molecular epidemiology of imipenem- or meropenem-non-susceptible E. coli in Taiwan.

Methods

Bacterial strains and susceptibility testing

Participating hospitals in the national survey identified imipenem- or meropenem-non-susceptible E. coli and sent all these isolates to a reference laboratory in National Health Research Institutes, Taiwan. A total of 32 imipenem- or meropenem-non-susceptible E. coli isolates were consecutively collected from eight hospitals participating in 2010 (five medical centers and three regional hospitals), with 43 collected from 17 hospitals (eight medical centers and nine regional hospitals) in 2012 [14]. All the isolates were from individual cases. This study was approved by the institutional review board of Kaohsiung Medical University Hospital (IRB No. KMUH-IRB-2 0130328). The isolates were obtained as part of routine hospital care procedures, and written informed consent for participation in the study was waived. The primary screening for carbapenem resistance was performed by the individual participating hospitals using the disc diffusion method. Species identification was performed by the individual participating hospitals using the disc diffusion method, and fingerprints of the plasmids were generated from these transconjugants using the standard alkaline lysis method, and fingerprints of the plasmids were generated by digestion with HincII or PvuII (New England Biolabs, Beverly, MA).

Pulsed-field gel electrophoresis (PFGE)

Total DNA was prepared, and PFGE was performed as described [18]. The restriction enzyme XbaI (New England Biolabs, Beverly, MA) was used at the temperature suggested by the manufacturer. The restriction fragments were separated by PFGE in a 1% agarose gel (Bio-Rad, Hercules, CA) in 0.5× TBE buffer (45 mM Tris, 45 mM boric acid, and 1.0 mM EDTA, pH 8.0) for 22 h at 200 V at a temperature of 14°C, with ramp times of 2–40 s using a CHEF Mapper apparatus (Bio-Rad Laboratories, Richmond, CA). The Dice coefficient was used to calculate similarities, and the unweighted pair-group method with the arithmetic mean method was used for the cluster analysis with BioNumerics software version 5.10 (Applied Maths, St-Martens-Latem, Belgium). Similarity PFGE patterns Hospital ST Cluster.

Isolation and analysis of outer membrane proteins

Bacterial outer membrane proteins (OMPs) were prepared as described [19]. The OMPs were then separated
by sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE) through 7.5% polyacrylamide-6 M urea gels and visualized by Coomassie Blue staining (Bio-Rad). A reference strain, *E. coli* ATCC25922, was included as a control. Figure 1 shows representative SDS-PAGE results to illustrate the interpretation of OmpC and OmpF loss.

**Multi-locus sequence typing (MLST)**

MLST with seven housekeeping genes [20], *adk* (adenylate kinase), *fumC* (fumarate hydratase), *gyrB* (DNA gyrase), *icd* (isocitrate dehydrogenase), *mdh* (malate dehydrogenase), *purA* (adenylosuccinate synthetase), and *recA* (ATP/GTP motif), was performed on all isolates according to the protocol described on the *E. coli* MLST website (http://mlst.ucc.ie/mlst/dbs/Ecoli/documents/primersColi_html). The allele sequences and sequence types (STs) were verified at the http://mlst.ucc.ie/mlst/dbs/Ecoli/ website.

**Results and discussion**

All isolates were resistant to cefazolin, cefotaxime, ceftriaxone, cefoxitin, and ertapenem. With the exception of amikacin, the rates of resistance to the other tested antimicrobial agents increased in 2012. For the eight hospitals that participated in both the 2010 and 2012 surveillance projects, the resistance rates of imipenem, meropenem, doripenem, and cefepime increased significantly (*P* < 0.05) (Table 1). Indeed, the resistant rates to imipenem, meropenem, and doripenem were 56.3%, 31.3%, and 15.6%, respectively, in 2010 and increased to 72.1%, 58.1%, and 51.2%, respectively, in 2012. All isolates were susceptible to tigecycline and colistin in 2010, whereas the resistant rates to tigecycline and colistin were 7.0% and 2.3%, respectively, in 2012.

Of the 75 *E. coli* isolates, five were not typable by PFGE. No major cluster was found, except for two pulsortypes with 4 and 2 isolates each (Figure 2). The PFGE results suggested that clonal spread was not responsible for the emergence of carbapenem-resistant *E. coli*.

Based on MLST, ST131 was found to be the major sequence type. Of the 75 *E. coli* isolates, ST131 was detected in 25 isolates (9 isolates in 2010 and 16 isolates in 2012). Seven isolates were assigned to ST410, and six isolates were assigned to ST457. ST405 and ST101 were found in three isolates each. The remaining isolates exhibited diverse ST types. The isolates of MLST type ST131 showed no significant difference in distribution in 2010 and 2012 and displayed highly diverse PFGE patterns.

In 2010, all the isolates were negative for KPC-, NDM-, VIM-, and OXA-carbapenemases, though one isolate was confirmed to harbor *bla* _IMP-8_. In 2012, one KPC-2-producing isolate and one NDM-1-producing isolate were detected, whereas no IMP-, VIM-, and OXA-type carbapenemases were found.

In Asia, KPC-producing Enterobacteriaceae was first detected in *K. pneumoniae* in China in 2004 [21] and was also soon found in *Citrobacter freundii*, *E. coli*, and *Serratia marcescens* [22,23]. In Taiwan, the first three KPC-2-positive patients were detected in *K. pneumoniae* isolated from patients having been hospitalized in China [24,25]. Since then, KPC-2-producing *K. pneumoniae* has been increasingly reported in Taiwan [26], though few cases of KPC-positive *E. coli* have been reported [27]. In the present report, we identify the first KPC-2-positive *E. coli* from Taiwan. This KPC-2-containing *E. coli* was obtained from a 78-year-old female who had not been abroad but was transferred from a regional hospital to a middle Taiwan medical center for a urinary tract infection. The KPC-2-containing isolate also produced TEM-1, CMY-2, and CTX-M-3/CTX-M-22 β-lactamases and was classified as MLST sequence type 410 (ST410). To date, KPC-producing *E. coli* has only been reported in Israel, the USA, China, Brazil, France, Greece, and Ireland [10,12,22,28-31], and two major sequence types containing KPC-carbapenemases have been reported. ST131 was reported in France [31], the USA [27], and Ireland [30]; ST410 was reported in Greece [10] and Israel [1] (ST471 in the Pasteur Institute typing
ase genes, which are commonly found in NDM-1 producer possessed TEM-1 and CMY-2 but did not exhibit OmpC/F loss. Most of the isolates had lost both OmpC and OmpF. Sixteen (21.3%) showed the loss of at least one porin, whereas 42 (56%) showed no porin loss. Sixty-six (88%) showed OmpC loss and 29 (39%) showed OmpF loss. Ten (13.4%) isolates had lost both OmpC and OmpF. Sixteen (21.3%) exhibited OmpC loss, and ten (13.3%) exhibited OmpF loss. Sixty-six (88%) showed OmpC loss and 29 (39%) showed OmpF loss. Ten (13.4%) isolates had lost both OmpC and OmpF. Sixteen (21.3%) exhibited OmpC loss, and ten (13.3%) exhibited OmpF loss.

We also report the first NDM-1-harboring E. coli isolate in Taiwan. Interestingly, an NDM-1-positive K. pneumoniae was detected in the same hospital during the same period and was included in the study to compare the two NDM-1-containing plasmids. The two NDM-1 plasmids from K. pneumoniae and E. coli were successfully transferred to the recipient isolate E. coli J53. Additionally, the plasmid digestion profiles of the two NDM-1 plasmids revealed different patterns (Figure 3), indicating that plasmid spread is less likely. Our E. coli NDM-1 producer possessed TEM-1 and CMY-2 but did not encode CTX-M β-lactamases and 16S rRNA methylase genes, which are commonly found in blaNDM-1-positive isolates [32]. Thus far, ten sequence types (ST101, ST405, ST648, ST90, ST410, ST156, ST131, ST167, ST224, and ST38) of E. coli have been reported to contain NDM-1 [33]. However, the ST type of the NDM-1 clone described herein is ST345, which has not yet been reported to harbor NDM-1. This finding supports a conclusion that blaNDM-1 occurs in E. coli belonging to diverse phylogenetic lineages [34] and also emphasizes the need to study the plasmids carrying blaNDM-1 in E. coli.

Table 1. Antimicrobial susceptibility testing results for carbapenem-non-susceptible E. coli isolates in 2010 and 2012

| Antibiotics | 2010 (n = 32) | 2012 (n = 43) |
|-------------|--------------|--------------|
| Ertapenem   | 2 ≥ 8        | 1 ≥ 8        |
| Imipenem    | 1 ≥ 8        | 1 ≥ 8        |
| Meropenem   | 0.12- ≥ 8    | 0.5- ≥ 8     |
| Doripenem   | 0.12- ≥ 4    | 0.5- ≥ 4     |
| Amikacin    | ≤4-64        | ≤4-32        |
| Gentamicin  | ≤1- ≥ 16     | ≤1- ≥ 16     |
| Cefazolin   | ≥32          | ≥32          |
| Ceftazidine | ≥32          | ≥32          |
| Cefotaxime  | 4- ≥ 64      | 32- ≥ 64     |
| Cefoxitin   | ≥32          | ≥32          |
| Ceftazidime | ≥32          | ≥32          |
| Cefepime    | 0.25- ≥ 32   | 2- ≥ 32      |
| Ciprofloxacin| 0.06- ≥ 4    | ≤0.06- ≥ 4   |
| Tigecycline | ≤0.25-1      | ≤0.25-1      |
| Colistin    | ≤0.5-2       | ≤0.5-2       |
| SXT         | 0.06- ≥ 16   | 2/38- ≥ 4/76 |

*SXT: Trimethoprim/sulfamethoxazole. Trimethoprim/sulfamethoxazole MICs are presented according to the concentration of trimethoprim in 2010.

The 75 carbapenem-non-susceptible E. coli isolates showed the loss of at least one porin, whereas 42 (56%) isolates had lost both OmpC and OmpF. Sixteen (21.3%) isolates exhibited OmpF loss, and ten (13.3%) isolates exhibited OmpC loss. Our study revealed that the main mechanism of imipenem or meropenem non-susceptibility in Taiwan is AmpC β-lactamase CMY-2 and DHA-1 in combination with OmpC/F loss (Table 2). It has been previously verified that such a combination of mechanisms can contribute to carbapenem resistance [6,7]. Most of the isolates were CMY producers (94.7%), and this most common CMY enzyme (CMY-2) of carbapenem-non-susceptible E. coli is also frequently found in cephamycin-resistant E. coli in community-acquired urinary tract infections in Taiwan [35].

E. coli sequence type ST131 is a pandemic clone associated with the CTX-M-15 gene and is resistant to fluoroquinolones [36]. Clone ST131 potentially harbors...
Figure 2 A dendrogram of the pulse-field gel electrophoresis (PFGE) fingerprinting results and the ST types of 70 typable \textit{E. coli} isolates.
a variety of $\beta$-lactamase genes, most commonly CTX-M $\beta$-lactamases, followed by TEM, SHV, and CMY $\beta$-lactamases [13], and its dissemination has contributed to the spread of CTX-M-15-producing *E. coli* [37]. Of the 75 carbapenem-non-susceptible *E. coli* isolates, 25 (33.3%) were the ST131 type; of these, 23 isolates displayed a resistant to ciprofloxacin. However, most of the isolates (18/25, 72%) did not produce CTX-M-type $\beta$-lactamases. Thus, our results showed that *E. coli* ST131 is the predominant ST type of carbapenem non-susceptible *E. coli* in Taiwan but that it is not highly associated with CTX-M ESBLs. Our findings are similar to the results of Kim et al. [27] and support the conclusion that the ability of the ST131 clone to acquire resistance genes under selective pressure could be high.

We found that the low prevalence of CTX-M-type $\beta$-lactamases was most likely linked to the identification of a low amikacin resistant rate in this study. Amikacin resistance mediated by 16S rRNA methylase (*armA* and *rmtB*) in Gram-negative bacteria is an emerging resistance mechanism [38], and our previous study found that the 16S rRNA methylase gene (*armA* and/or *rmtB*) and the CTX-M gene were located on the same plasmid [39]. The low prevalence of CTX-M-type $\beta$-lactamases and the low amikacin resistant rate suggested the lack of an endemic plasmid to transfer both *bla*$_{CTX-M}$ and 16S rRNA methylase genes for carbapenem-non-susceptible *E. coli*.

### Conclusions

OmpC and/or OmpF deficiency combined with AmpC (major CMY-2 and DHA-1) was found to be the major mechanism for the development of carbapenem non-susceptibility in Taiwan. The dominant clone of carbapenem-non-susceptible *E. coli* in Taiwan is ST131,
which has also been found worldwide, and the high prevalence of this ST type illustrates the epidemic potential of this clone. The introduction of KPC-2 and NDM-1 into _E. coli_ in Taiwan warrants further monitoring with regard to the epidemiology of carbapenem resistance, the resistance mechanisms, and the potential epidemic clones.

**Competing interests**

The authors declare that they have no competing interests.

**Authors’ contributions**

ML and PLL contributed to the data analysis and wrote the primary draft of the manuscript. LKS, JCL, TLW, CPF, JTW, PLL, and YCC participated in the study design and experiments. PLL and YCC reviewed and revised the paper. All authors have read and approved the final manuscript.

**Acknowledgements**

This work was funded by the project DOH101-DC-1024 (Epidemiology of multidrug-resistant bacteria in Taiwan: mechanisms of antibiotic resistance and clinical relevance) grant from the Taiwan Centers for Disease Control. All authors declare no conflict of interest. The authors thank the Taiwan Carbapenem Resistance Study Group for the collection of isolates from Keelung Chang Gung Memorial Hospital, Tri-Service General Hospital, Taipei Veterans General Hospital, Linkou Chang Gung Memorial Hospital, China Medical University Hospital, Chiayi Chang Gung Memorial Hospital, Kaohsiung Chang Gung Memorial Hospital, Kaohsiung Medical University Hospital, National Taiwan University Hospital, Taoyuan Armed Forces General Hospital, Buddhist Tzu Chi General Hospital, Hualien Armed Forces General Hospital, National Yang-Ming University Hospital, Taichung Armed Forces General Hospital, Chi Mei Medical Center, Kaohsiung Armed Forces General Hospital, and Kaohsiung Municipal Hsiao-Kang Hospital. We would like to express our gratitude to Dr. Jodge Jacoby for providing the _E. coli_ J53 recipient strain.

**Author details**

1. National Institutes of Infectious Diseases and Vaccinology, National Health Research Institutes, Maoli, Taiwan. 2. Division of Infectious Diseases and Tropical Medicine, Department of Internal Medicine, Tri-Service General Hospital, National Defense Medical Center, Taipei, Taiwan. 3. Department of Clinical Pathology, Linkou Chang Gung Memorial Hospital, Taoyuan, Taiwan. 4. Section of Infectious Diseases, Department of Medicine, Taipei Veterans General Hospital, Taipei, Taiwan. 5. Division of Infectious Diseases, Department of Medicine, National Taiwan University Hospital, Taipei, Taiwan. 6. Department of Internal Medicine, Kaohsiung Medical University Hospital, 100 Tzyou 1st Road, Kaohsiung City, Taiwan. 7. College of Medicine, Kaohsiung Medical University, 100 Tzyou 1st Road, Kaohsiung City, Taiwan. 8. Department of Internal Medicine, Kaohsiung Medical University Hospital, 100 Tzyou 1st Road, Kaohsiung City, Taiwan. 9. Department of Internal Medicine and Medical Research, Chi Mei Medical Center, Tainan, Taiwan. 10. Department of Internal Medicine, Chi Mei Medical Center, Liouyung, Tainan, Taiwan.

Received: 26 August 2013 Accepted: 12 December 2013

**References**

1. Goren MG, Navon-Venezia S, Chmelitsky I, Carmeli Y: Carbapenem-resistant KPC-2-producing _Escherichia coli_ in a Tel Aviv Medical Center, 2005 to 2008. Antimicrob Agents Chemother 2010, 54(6):2687-2697.

2. Schwaber MJ, Carmeli Y: Carbapenem-resistant _Enterobacteriaceae_: a potential threat. JAMA 2008, 300(24):2911–2913.

3. Patel JB, Rasheed JK, Kitchel B: Carbapenemases in _Enterobacteriaceae_: activity, epidemiology, and laboratory detection. Clin Microbiol Newsl 2009, 31(6):65–62.

4. Queenan AM, Bush K: Carbapenemases: the versatile beta-lactamases. Clin Microbiol Rev 2007, 20(3):440–458.

5. Poirel L, Hentzer C, Spiçq C, Nordmann P: In vivo acquisition of high-level resistance to imipenem in _Escherichia coli_. J Clin Microbiol 2004, 42(8):3831–3833.

6. Stapleton PD, Shannon KP, French GL: Carbapenem resistance in _Escherichia coli_ associated with plasmid-determined CMY-2 beta-lactamase production and loss of an outer membrane protein. Antimicrob Agents Chemother 1999, 43(5):1206–1210.

7. Goossens WH, van der Bij AK, van Boxtel R, Pitout JD, van Ulsen P, Melles DC, Tommassen J: Antibiotic trapping by plasmid-encoded CMY-2 beta-lactamase combined with reduced outer membrane permeability as a mechanism of carbapenem resistance in _Escherichia coli_. Antimicrob Agents Chemother 2013, 57:3941–3949.

8. Patel G, Bonomo RA: “Stormy waters ahead”: global emergence of carbapenemases. Front Microbiol 2013, 4:48.

9. Livermore DM: Current epidemiology and growing resistance of gram-negative pathogens. Korean J Intern Med 2012, 27(2):128–142.

10. Navon-Venezia S, Chmelitsky I, Leavitt A, Schwaber MJ, Schwarz D, Carmeli Y: Plasmid-mediated imipenem-hydrolyzing enzyme KPC-2 among multiple carbapenem-resistant _Escherichia coli_ clones in Israel. Antimicrob Agents Chemother 2006, 50(9):3098–3101.

11. Nordmann P, Poirel L: Emerging carbapenemases in gram-negative aerobes. Clin Microbiol Infect 2002, 8(6):321–331.

12. Bratu S, Brooks S, Burney S, Kochar S, Gupta J, Landman D, Quale J: Detection and spread of _Escherichia coli_ possessing the plasmid-borne carbapenemase KPC-2 in Brooklyn, New York. Clin Infect Dis 2007, 44(7):972–975.

13. Rogers BA, Sidibjak HE, Paterson DL: _Escherichia coli_ O25b-ST131: a pandemic, multiresistant, community-associated strain. J Antimicrob Chemother 2011, 66(1):1–14.

14. Clinical and Laboratory Standards Institute: Performance Standards for Antimicrobial Susceptibility Testing, Twenty-Second informational supplement. CLSI M100-S22-U. Wayne, PA; 2011.

15. Clinical and Laboratory Standards Institute: Methods for Dilution Antimicrobial Susceptibility Tests for Bacteria That Grow Aerobically. Approved standard Ninth Edition. Wayne, PA; 2012.

16. Alvarez M, Tran JH, Chow N, Jacoby GA: Epidemiology of conjugative plasmid-mediated AmpC beta-lactamases in the United States. Antimicrob Agents Chemother 2004, 48(5):1533–1537.

17. Eckert C, Gautier V, Saladin-Allard M, Hidi R, Vertet C, Ould-Hocine Z, Barnaud G, Delille F, Rossier A, Lambert T, et al: Dissemination of CTX-M-type beta-lactamases among clinical isolates of _Enterobacteriaceae_ in Paris, France. Antimicrob Agents Chemother 2004, 48(4):1249–1255.

18. D’Agata EM, Gerrits MM, Tang YW, Samore M, Kusters JG: Comparison of pulsed-field gel electrophoresis and amplified fragment-length polymorphism for epidemiological investigations of common nosocomial pathogens. Infect Control Hosp Epidemiol 2001, 22(9):550–554.

19. Freire P, Vieira HL, Furtado AR, de Pedro MA, Arraiano CM: Effect of the morphogene _b0a_ on the permeability of the _Escherichia coli_ outer membrane. FEMS Microbiol Lett 2006, 260(1):106–111.

20. Wirth T, Falush D, Lan R, Colles F, Mensa P, Wieler LH, Karch H, Reeves PR, Maiden MC, Ochman H, et al: Sex and virulence in _Escherichia coli_: an evolutionary perspective. Mol Microbiol 2006, 60(5):1135–1151.

21. Wei ZQ, Du XX, Yu YS, Shen P, Chen YG, Li LJ: Plasmid-mediated KPC-2 in a _Klebsiella pneumoniae_ isolate from China. Antimicrob Agents Chemother 2007, 51(2):763–765.

22. Cai JC, Zhou HW, Zhang R, Chen GX: Emergence of _Serratia marcescens_, _Klebsiella pneumoniae_, and _Escherichia coli_ isolates possessing the plasmid-mediated carbapenem-hydrolyzing beta-lactamase KPC-2 in intensive care units of a Chinese hospital. Antimicrob Agents Chemother 2008, 52(6):2014–2018.

23. Nordmann P, Guzon G, Naas T: The real threat of _Klebsiella pneumoniae_ carbapenemase-producing bacteria. Lancet Infect Dis 2009, 9(4):228–236.

24. Chung KP, Tseng SP, Huang YT, Tsai TH, Tseng LJ, Hsueh PR: Arrival of _Klebsiella pneumoniae_ carbapenemase (KPC)-2 in Taiwan. J Antimicrob Chemother 2011, 66(5):1182–1184.

25. Lauderdale TL, Shi ZY, Lin CF, Lai JF, Tan MC, Wang JT, Chang SC: KPC-2-producing sequence type 11 _Klebsiella pneumoniae_ detected in Taiwan. Antimicrob Agents Chemother 2012, 56(4):2207–2208.

26. Chiu SK, Wu TL, Chuang YC, Lin JC, Fang CP, Lu PL, Wang JT, Wang LS, Sui LK, Yeh KM: National surveillance study on carbapenem nonsusceptible _Klebsiella pneumoniae_ in Taiwan: the emergence and rapid dissemination of KPC-2 carbapenemase. PLoS One 2013, 8(7):e69428.

27. Kim YA, Qureshi ZA, Adams-Haduch JM, Park YS, Shutt KA, Doi Y: Features of infections due to _Klebsiella pneumoniae_ carbapenemase-producing _Escherichia coli_: emergence of sequence type 131. Clin Infect Dis 2012, 55(2):224–231.
29. Mavroidi A, Miriagou V, Malli E, Stefos A, Dalekos GN, Tzouvelekis LS, Petinaki E: Emergence of Escherichia coli sequence type 410 (ST410) with KPC-2 beta-lactamase. Int J Antimicrob Agents 2012, 39(3):247–250.

30. Morris D, Boyle F, Ludden C, Condon I, Hale J, O'Connell N, Power L, Boo TW, Dharji H, Lavallee C, et al: Production of KPC-2 carbapenemase by an Escherichia coli clinical isolate belonging to the international ST131 clone. Antimicrob Agents Chemother 2011, 55(10):4933–4934.

31. Naas T, Cuzon G, Gaillot O, Courcol R, Nordmann P: When carbapenem-hydrolyzing beta-lactamase Kpc meets Escherichia coli ST131 in France. Antimicrob Agents Chemother 2011, 55(10):4933–4934.

32. Bercot B, Poirel L, Nordmann P: Updated multiplex polymerase chain reaction for detection of 16S rRNA methylases: high prevalence among NDM-1 producers. Diagn Microbiol Infect Dis 2011, 71(4):442–445.

33. Castanheira M, Deshpande LM, Mathai D, Bell JM, Jones RN, Mendes RE: Early dissemination of NDM-1- and OXA-181-producing Enterobacteriaceae in Indian hospitals: report from the SENTRY Antimicrobial Surveillance Program, 2006–2007. Antimicrob Agents Chemother 2011, 55(3):1274–1278.

34. Mushraq S, Irfan S, Sarma JB, Dounith M, Pike R, Pitout J, Livermore DM, Woodford N: Phylogenetic diversity of Escherichia coli strains producing NDM-type carbapenemases. J Antimicrob Chemother 2011, 66(9):2002–2005.

35. Wu TL, Chia JH, Su LH, Chiu CH, Kuo AJ, Ma L, Siu LK: CMY-2 beta-lactamase-carrying community-acquired urinary tract Escherichia coli: genetic correlation with Salmonella enterica serotypes Choleraesuis and Typhimurium. Int J Antimicrob Agents 2007, 29(4):410–416.

36. Coque TM, Novais A, Carattoli A, Poirel L, Pitout J, Peixe L, Baquero F, Canton R, Nordmann P: Dissemination of clonally related Escherichia coli strains expressing extended-spectrum beta-lactamase CTX-M-15. Emerg Infect Dis 2008, 14(2):195–200.

37. Peirano G, Pitout JD: Molecular epidemiology of Escherichia coli producing CTX-M beta-lactamases: the worldwide emergence of clone ST131 O25:H4. Int J Antimicrob Agents 2010, 35(4):316–321.

38. Doi Y, Arakawa Y: 16S ribosomal RNA methylation: emerging resistance mechanism against aminoglycosides. Clin Infect Dis 2007, 45(1):88–94.

39. Ma L, Lin CJ, Chen JH, Fung CP, Chang FY, Lai YK, Lin JC, Siu LK: Widespread dissemination of aminoglycoside resistance genes armA and mmtB in Klebsiella pneumoniae isolates in Taiwan producing CTX-M-type extended-spectrum beta-lactamases. Antimicrob Agents Chemother 2009, 53(1):104–111.

doi:10.1186/1471-2334-13-599

Cite this article as: Ma et al.: Updated molecular epidemiology of carbapenem-non-susceptible Escherichia coli in Taiwan: first identification of KPC-2 or NDM-1-producing E. coli in Taiwan. BMC Infectious Diseases 2013 13:599.